Integra LifeSciences Holdings Corporation · NASDAQ:IART
Integra LifeSciences — Q1 2022 Earnings Presentation
19 slides from Integra LifeSciences's earnings presentation, Apr 27, 2022
Slide 1: Q1 2022 Earnings Presentation
Q1 2022 EARNINGS PRESENTATION APRIL 27, 2022
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties and reflect the Company's judgment as of the date of this presentation. All statements, other than statements of
Slide 3: Non-GAAP Financial Measures
Non-GAAP Financial Measures In addition to our GAAP results, we provide certain non-GAAP measures, including organic revenues, adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA"), adjusted net income, adjusted earnings per diluted share, free cash flow and adjusted fre
Slide 4: Executing On Our Strategy
Executing On Our Strategy Q1 Financial Performance Business Highlights Total revenue $376.6 million – above high end of guidance Broad surgical procedure recovery across portfolio • Procedure volumes steadily improved in March • ≥ 5% organic growth in CSS and TT • Supply met accelerated demand Focus
Slide 5: First Quarter Financial Highlights
First Quarter Financial Highlights • 4.6% reported growth Revenue $376.6 • $12M above high end of guidance range Organic • 5.0% Global CSS organic growth • 6.0% U.S. organic growth Revenue 5.6% Growth1 • 6.9% Global TT organic growth • 4.8% Intl. organic growth Adj EBITDA 24.8% Adj. gross margins in
Slide 6: Codman Specialty Surgical Q1 Revenue
Codman Specialty Surgical Q1 Revenue Revenues Q1’22 Q1’21 Growth Reported $247.3M $241.2M 2.5% Q1 2022 Organic1 $248.4M $236.6M 5.0% Revenue Composition Q1 2022 Growth and Performance Drivers2 Instruments Neurosurgery Instruments International 21.3% 5.8% 2.1% Mid-Single Digits • Neurosurgery – High
Slide 7: Tissue Technologies Q1 Revenue
Tissue Technologies Q1 Revenue Revenues Q1’22 Q1’21 Growth Reported $129.3M $118.8M 8.8% Q1 2022 Organic1 $127.1M $118.8M 6.9% Revenue Composition Q1 2022 Growth and Performance Drivers2 Private Wound Reconstruction Private Label International Label 26.8% 4.1% 15.2% Mid-Single Digits • Wound Reconst
Slide 8: Q1 2022 Financial Results ($M except per share data)
Q1 2022 Financial Results ($M except per share data) Total Revenue Adj. Gross Profit Adj. EBITDA Adj. EPS Reported 4.6% 40bps Margin (20bps) Margin +7.2% Organic 5.6% $360.1 $376.6 $93.5 $254.8 $89.9 $242.4 $40 0.0 1 $30 0.0 20 100 1.2 $0.8 0 1.2 $35 0.0 $25 0.0 15 90 1 $0.7 5 $0.74 1 $0.69 80 $30 0
Slide 9: Balance Sheet and Cash Flow Performance
Balance Sheet and Cash Flow Performance Operating Cash Flow, Free Cash Flow ($M) & Adj. FCF Conversion (%) Summary Balance Sheet ($M) 12/31/21 3/31/22 FCF Capex 350 Cash and Cash Equivalents $513 $407 $287.7 300 $252.1 $50.7 Total Debt $1,563 $1,562 $29.0 250 Net Debt $1,050 $1,155 90 $69.1 200 80 $
Slide 10: Q2 2022 and FY 2022 Outlook
Q2 2022 and FY 2022 Outlook Q2 Reported Revenue Guidance Bridge ($M) Q2 2022 2.8% - 4.8% $390 $392 - $400 • Revenue: $392M-$400M ~($2) ~($7) • Reported Growth +0.5% to +2.5% • Organic Growth +2.8% to +4.8% • Adj. EPS $0.78 - $0.82 2022 Reported Revenue Guidance Bridge ($M) FY 2022 3.8% - 5.2% • Reaf
Slide 11: Integra Growth Catalysts
Integra Growth Catalysts Near- to Mid-Term Growth Catalysts First Quarter Performance & Progress Diverse and Inclusive Teams • Post-COVID procedure growth recovery Broad-based organic growth despite Focused on COVID-related disruptions in beginning Getting Things Rigorous • International opportuni
Slide 12: Appendix: Non-GAAP Reconciliations
Appendix Non-GAAP Reconciliations
Slide 13: First Quarter 2022 Financial Results
First Quarter 2022 Financial Results % of Revenues Q1 2022 Q1 2021 Change Total Revenues $376.6 $360.1 4.6% Gross Margin 62.1% 59.5% +260BPS Adj. Gross Margin(1) 67.7% 67.3% +40BPS Net Income $32.9 $45.4 (27.5%) Adj. Net Income(1) $62.0 $59.0 5.1% Adj. EBITDA Margin(1) 24.8% 25.0% -20BPS Diluted Sha
Slide 14: First Quarter 2022 Organic Growth Reconciliation
First Quarter 2022 Organic Growth Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 Neurosurgery $194.7 $189.3 Instruments $52.6 $52.0 Total Codman Specialty Surgical $247.3 $241.2 Wound Reconstruction and Care $94.6 $88.7 Private Label $34.7 $30.1 Total Tissue T
Slide 15: First Quarter 2022 Adjusted EBITDA Margin Reconciliation
First Quarter 2022 Adjusted EBITDA Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 GAAP Net Income $32.9 $45.4 Depreciation 9.6 9.4 Intangible asset amortization 20.1 22.5 Other (income), net (2.1) (3.3) Interest expense, net 10.3 11.2 Income tax expense
Slide 16: First Quarter 2022 Adjusted EPS Reconciliation
First Quarter 2022 Adjusted EPS Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 GAAP Net Income $32.9 $45.4 Acquisition, divestiture and integration-related charges (1) 0.6 (27.0) Structural optimization charges 6.3 3.9 EU Medical Device Regulation 9.5 5.7 Inta
Slide 17: First Quarter 2022 and 2021 (TTM) Adjusted Free Cash Flow Reconciliation
First Quarter 2022 and 2021 (TTM) Adjusted Free Cash Flow Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 TTM 2022 TTM 2021 Net Cash from Operating Activities $44.3 $69.1 $287.7 $252.1 Purchases of Property and Equipment ($9.3) ($6.7) ($50.7) ($29.0) Free Cash
Slide 18: First Quarter 2022 Gross Margin Reconciliation
First Quarter 2022 Gross Margin Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 Reported Gross Profit $234.1 $214.2 Structural optimization charges 2.9 1.8 Acquisition, divestiture and integration-related charges 0.9 8.0 EU Medical Device Regulation 0.7 0.3 Int
Slide 19: First Quarter 2022 Adjusted SG&A Reconciliation
First Quarter 2022 Adjusted SG&A Reconciliation Note: Numbers may not add due to rounding (In millions) Q1 2022 Q1 2021 Reported SG&A $159.9 $156.6 Structural optimization charges 3.3 1.6 Acquisition, divestiture and integration-related charges 2.1 7.8 EU Medical Device Regulation 3.5 2.1 Adjusted S
Integra LifeSciences Holdings — Q1 2022 Earnings Presentation on 6ix